Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）

To evaluate the efficacy and safety of SYS6010 versus platinum-based chemotherapy in participants with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC)

Trial Details

NCT ID

NCT06927986

Phase

PHASE3

Sponsor

CSPC Megalith Biopharmaceutical Co.,Ltd.

Status

RECRUITING

Cancer Type

Non-Small Cell (NSCLC) Lung Cancer

Interventions

SYS6010
Pemetrexed
Cisplatin
Carboplatin

Locations (sample)

Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

Aged 18-75 (inclusive) years old, male or females;
Patients with pathologically confirmed locally advanced or metastatic NSCLC, including those with stage IIIB or IIIC based on 8th edition of the AJ…
Presence of at least one EGFR-sensitive mutation;
At least one measurable lesion confirmed by CT or MRI scan according to RECIST v1.1 criteria;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →